LANARKSHIRE AREA DRUG & THERAPEUTICS COMMITTEE

Minute of the meeting held on Wednesday 18th September 2013 at 10am in the Boardroom, NHS Lanarkshire HQ, Kirklands, Bothwell

PRESENT: Anne Buchanan [Admin Support]     Dr Mehrdad Malekian [Chair]
Gillian Corbett                      Dr Philip McMenemy
Caroline Delahunty                  Mr John Milne
Mrs Dorothy Findlay [on behalf of Ann Auld]  Dr Colin Ooi
Mrs Christine Gilmour              Mrs Karen Patterson
Ms Fiona Graham                    Mrs Gail Richardson
Dr Harpreet Kohli                  Dr Vijay Sonthalia
Dr Alwaly Majumdar

2013/70 Apologies
Elaine Aggleton, Ann Auld, Dr Stephanie Dundas, Linda Johnstone, Mr George Lindsay, Mr James Smith,

2013/71 Minute of previous meeting
The minute of the previous meeting held on Wednesday 17th July was accepted as a true record.

2013/72 Matters arising from the previous meeting

(a) Amendments to draft minute of 19th June 2013
Ms Buchanan confirmed that the minute of June meeting had been changed and updated.

(b) Antiplatelets
SAS are reluctant to deviate from original national protocol giving patients with STEMI a loading dose of clopidogrel, despite changes in treatment with introduction of Ticagrelor/Prasugrel.

SAS would like a new national protocol but this is unlikely to happen as different strategies have been adopted by individual health boards across Scotland. As a result, in view of concerns regarding risk of bleeding with dual loading, majority of patients with STEMI in Lanarkshire are not loaded with new antiplatelets at time of presentation as they would have already been given clopidogrel by SAS crew. There are plans for further dialogue with SAS in order to reach a regional (west of Scotland) agreement.

(c) Remote Prescribing
This is not ready for presentation further work is required.

2013/73 Scottish Medicines Consortium Advice

a) Full submissions:

1. Rituximab 100mg, 500mg solution for infusion (MabThera®) SMC No. (894/13)

FG/KP

rituximab (Mabthera)
FINAL August 2013.d

This was noted by the committee.
2. rifaximin 550mg film-coated tablets (Targaxan®) SMC No. (893/13)

Ms Graham to take to Gastroenterology Formulary Sub Group for comments.
Ms Patterson to take to Dr Tim Reilly.

3. ocriplasmin, 0.5mg/0.2 mL, concentrate for solution for injection (Jetrea®)
SMC No. (892/13)

This was noted by the committee.

4. lixisenatide 10microgram/0.2mL, 20microgram/0.2mL solution for injection in
pre-filled disposable pen (Lyxumia®)SMC No. (903/13)

Ms Graham to take to the Diabetes Formulary Sub Group.

5. aripiprazole 5mg, 10mg, 15mg, 30mg tablets, 10mg, 15mg orodispersible
tablets, 1mg/mL oral solution (Abilify®)SMC No. (891/13)

Ms Graham to take to The Mental Health D&T and Duncan Clark.

6. caffeine citrate, 20mg/mL, solution for infusion and oral solution (Peyona®)
SMC No. (814/12)

This was noted by the committee.

7. botulinum toxin type A 50, 100, 200 Allergan units/vial (Botox®) SMC No. (916/13)

Ms Graham to take to Urology Formulary Sub Group and Dr John Paul Leach.

8. carglumic acid 200mg dispersible tablets (Carbaglu®) SMC No. (899/13)

This was noted by the committee.
9. pertuzumab 30mg/mL concentrate for solution for infusion (Perjeta®) SMC No. (897/13)

This was noted by the committee.

10. nalmefene 18mg film-coated tablets (Selincro®) SMC No. (917/13)

Ms Graham to take to the Lanarkshire Addictions Team.

b) Abbreviated submissions:

1. medroxyprogesterone acetate 104mg/0.65mL suspension for subcutaneous depot injection (Sayana® Press) (No: 896/13)

Ms Graham to take to the Gynaecology Sub Group and Dr Eleanor Smith for comment.

2. etravirine 25mg, 100mg, 200mg tablets (Intelence®) (No. 901/13)

This was noted by the committee.

3. raltegravir 25mg, 100mg chewable and 400mg film-coated tablets (Isentress®) (No: 902/13)

raltegravir (Isentress®) is accepted for restricted use within NHS Scotland.

This was noted by the committee.

4. tenofovir disoproxil (as fumarate) 123mg, 163mg, 204mg film-coated tablets (Viread®) (No. 900/13)

This was noted by the committee.

5. tenofovir disoproxil (as fumarate) 245mg film-coated tablets (Viread®) (No. 904/13)

This was noted by the committee.
6. tenofovir disoproxil (as fumarate) 33mg/g oral granules (Viread®) (No. 905/13)

This was noted by the committee.

7. bimatoprost 0.3mg/mL plus timolol 5mg/mL, preservative-free, single-dose eye drops (Ganfort® Unit Dose Preservative Free) (No: 906/13)

Ms Graham to take to ophthalmology Formulary Sub Group for comment.

c) Non Submission:

1. eculizumab (Soliris®) 300 mg concentrate for solution for infusion (No: 915/13)

This was noted by the committee.

d) Resubmission

1. crizotinib, 200mg and 250mg, hard capsule (Xalkori®) SMC No.(865/13)

This was noted by the committee.

2. imatinib (Glivec ®) 100 mg / 400 mg film coated tablets (No: 923/13)

This was noted by the committee.

3. vismodegib (Erivedge ®) 150 mg hard capsules (No: 924/13)

This was noted by the committee.

2013/74 SMC Follow-up
None.

2013/75 ADTC Bulletin – No 72 August 2013
This was noted.

2013/76 Clinical Protocols

a. Antipsychotic
This has been approved at the mental Health D&T.

b. ADHD
As there is a growing area of ADHD in adults, a clinical protocol is required to be tabled at November’s meeting. Current IPTR not logical for adults as the current protocol is
c. *Eylea*
The committee considered the clinical protocol submitted and approved it with minor amendments for treatment naïve patients. The committee did not approve it’s use for switching patients who have been treated with other therapies.

2013/77 **Unlicensed Medicines**
Nil to report.

2013/78 **Lanarkshire Formulary**

1. **New Oral Anticoagulant**
   There is a link in the formulary to the new oral anticoagulant document.

2. **Freestyle Lite Meter**
   Was discontinued in August 2013.

3. **Phenytoin**
   There was a dose change of Phenytoin sodium for status epilepticus.

4. **Epipen**
   Dr Adrian Sie advised on the updates to the wording for Epipen.

5. **MHRA**
   No test dose is required for IV iron preparations. The advice from the MHRA is that caution should be exercised with every dose.

6. **Fentanyl Patches**
   The MHRA have advised that serotonin syndrome is a risk when used with certain antidepressants. The wording in the formulary will be altered to advise this.

7. **Metoclopramide**
   The EMA have advised that Metoclopramide should be used only up to 5 days the wording in the formulary will be altered to emphasis.

2013/79 **NICE/HIS Guidance**
Nil to report.

2013/80 **Medication and Clinical Risk in Lanarkshire**
This was noted by the committee.

2013/81 **Regional Cancer Prescribing Advisory Group**
Mr Milne talked through submitted papers and the committee noted the comments.

2013/82 **Correspondence**
SMC have circulated their list of specialist advisors and has asked boards to nominate appropriate Clinicians to fill identified gaps. Mrs Gilmour will contact SMC for further information.

2013/83 **AOCB**

a. **West of Scotland Individual Treatment Request Process**
   Mrs Gilmour advised that there would be no change in the NHS Lanarkshire IPTR process.

b. **Joint Medicine Information Service with Forth Valley**
   Mrs Gilmour advised that a Joint Medicines Information Service has been established between NHS Lanarkshire and NHS Forth Valley. This service is still in infancy and will deal with complex enquiries only.
Date of next meeting
Wednesday 23rd October 2013 at 10am in the conference room, Ground Floor, Kirklands Hospital.